Transcriptomic Drug Repurposing in Glioblastoma Multiforme: Single-Cell RNA Sequencing Reveals Novel Candidates Targeting Tumor-Associated Macrophage Pathways

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

We applied a scRNA-seq drug repurposing pipeline to GSE182109 (38,027 GBM cells, 29 Leiden clusters) to identify therapeutic candidates targeting tumor-associated macrophages and microglia. Differential expression analysis yielded 29,034 DE genes and 9,952 scored candidates. BNTX (delta opioid receptor antagonist, score 2280), BMS-754807 (IGF-1R/IR inhibitor, 2220), Wortmannin (PI3K inhibitor, 2180), and MG-132 (proteasome inhibitor, 2170) are top novel candidates. Cross-disease validation confirmed QL-XII-47 (MELK/FLT3, 2070), R-547 (CDK, 2100), KPT-330/selinexor (XPO1, 1990), SAR405838 (MDM2, 1970), and WZ-3105 (SRC/ABL, 1970) — the latter now in 20+ independent pipelines spanning autoimmune, neurological, and oncological indications. Companion to provisional patent application No. 32, Ritschel Research portfolio.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Computational Drug Discovery Methods Single-cell and spatial transcriptomics

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
27 March 2026
Language
EN
Document type
Preprint